CEGIR 7808: Use of Unsedated Transnasal Esophagoscopy (TNE) to Monitor Dietary Management of Eosinophilic Esophagitis in Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-01

Study Completion Date

2020-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test the effectiveness of utilizing Transnasal Esophagoscopy as a means of monitoring Eosinophilic Esophagitis patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-endoscopic Tracking of Disease Activity in Eosinophilic Esophagitis

NCT03834298

Eosinophilic Esophagitis

WITHDRAWN NA

Use of Esophageal String Test to Understand Symptoms, Inflammation, and Function in Eosinophilic Esophagitis

NCT03305653

Eosinophilic Esophagitis

COMPLETED NA

Prospective Multicenter Nationwide Registry of Children With Eosinophilic Esophagitis

NCT03858426

Eosinophilic Esophagitis

UNKNOWN

CEGIR 7807: Validation of Online Cohort of EGID Patients Enrolled in RDCRN CEGIR Contact Registry

NCT03382678

Eosinophilic Esophagitis

COMPLETED

OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

NCT02523118

Eosinophilic Gastrointestinal Disorders (EGIDs) Eosinophilic Esophagitis Eosinophilic Gastritis +2 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A participant with an established diagnosis of EoE who is undergoing Standard of Care treatment with a four or less food elimination diet (not including or counting foods restricted at time of EoE diagnosis) OR is on topical swallowed steroid therapy with any number of foods eliminated from the diet, is in histological remission, and has been recommended as part of Standard of Care to start a single new food introduction OR remove the swallowed steroid treatment by the subject's clinical allergist or gastroenterologist will be enrolled in the study. 14-17 days after the introduction of the clinically recommended single food antigen, a TNE will be performed to assess the esophageal mucosa. TNE will be performed every 2 weeks for six weeks (3 total TNE) to evaluate recurrence time of mucosal eosinophilia (\>15 eos/HPF), other histological changes, and patient tolerance to serial TNE. At week 6 a sedated esophagoscopy will be offered as an alternative choice to TNE if the participant chooses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Eosinophilic Esophagitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Phase

Treatment Phase will evaluate the effectiveness of Transnasal Esophagoscopy (TNE) as an acceptable form of monitoring Eosinophilic Esophagitis

Group Type OTHER

Transnasal esophagoscopy

Intervention Type OTHER

single food antigen introduction OR removal of topical swallowed steroid therapy followed by surveillance utilizing TNE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transnasal esophagoscopy

single food antigen introduction OR removal of topical swallowed steroid therapy followed by surveillance utilizing TNE

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participant must be able to understand and provide informed consent/assent
2. Males and females ages 5-22 years of age
3. History of an established diagnosis of EoE
4. Recent EGD or TNE (with in past 1 year) showing EoE remission (e.g. \<15 x eosinophils/hpf) and currently without significant symptoms attributed to EoE.
5. On a four food or less elimination diet not including or counting foods restricted at time of EoE diagnosis OR on swallowed topical steroid therapy with any number of foods eliminated from the diet.
6. Female subjects of childbearing potential must have a negative pregnancy test upon study entry
7. Female subjects with reproductive potential, must agree to use FDA approved methods of birth control for the duration of the study
8. Children and families have desire to reintroduce potential food allergens and either the food antigen has been recommended with plans for its introduction as part of Standard of Care by the child's allergist and/or gastroenterologist OR the swallowed topical steroid therapy has been recommended to be discontinued by the child's allergist and/or gastroenterologist.
9. Children and families willing to undergo unsedated serial TNE

Exclusion Criteria

1. Inability or unwillingness of a participant to give written informed consent or comply with study protocol
2. Bleeding disorder
3. Unwilling to undergo unsedated TNE
4. Unwilling or unable to come to hospital at least 3 times over 6 weeks.
5. Currently treated with a swallowed corticosteroid which is not being discontinued.
6. Treated with oral corticosteroids within 8 weeks of the start of the study.
7. More than one change is being made to the EoE treatment regimen (e.g., more than a single food is being reintroduced during the study period; the swallowed topical steroid is being discontinued at the same time a food is being introduced).
8. EoE has been symptomatic with clinically significant symptoms attributable to EoE including dysphagia, abdominal pain or vomiting in the period since endoscopy
9. The finding of uncontrolled cough, significant rhinorrhea or rhinitis obstructing nasal passages, oxygen saturations \<92% (high altitude normal saturation), temperature \>38 degrees Celsius, significant gastrointestinal illness within 1 week of TNE, or provider determination of significant illness during pre-procedure history and physical on the day that the TNE is planned.
10. Pregnancy, breast feeding or plans to become pregnant
11. Unable to complete study procedures including endoscopy.
12. Allergy to any material or medicine used for procedures
13. Use of investigational drugs within 16 weeks of participation
14. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

Minimum Eligible Age

5 Years

Maximum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No